Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Attends the CCC2018

[2018-02-08] 

Beijing, China – From January 19 to January 21, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the Ninth Clinical Cardiology Conference ("CCC2018") and the 15th Coronary Interventional Salon of China ("CISC2018") to display Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and other innovative products as well as hosted a case competition focused on the treatment of complex lesion and CTO re-infarction.
 
During the case competition, Director Lianglong Chen of Fujian Medical University Union Hospital, Director Jinghua Liu of Beijing Anzhen Hospital, Director Hongliang Cong of Tianjin Chest Hospital, Director Jianping Luo of Beijing Jingmei Group General Hospital, and Professor Zhan Lv of Affiliated Hospital of North Sichuan Medical College were invited as guest speakers to review and moderate the cases. Two complex lesion cases, respectively presented by Director Liming Gao of Shanghai East Hospital and Director Yimin Wang of Linfen People's Hospital, shared the first place for their outstanding surgical skill and brilliant case review. Since 2016, MicroPort® hosted the case competition and has received positive feedback in various national-level congresses. The competition builds a communication platform between young physicians and top industry experts and creates new learning opportunities for primary physicians.
 
During the meeting, MicroPort® R&D staff exchanged ideas with Professor Shubin Qiao of Fuwai Hospital and Professor Dongxing Ma of Military General Hospital regarding Firefighter™ PTCA Balloon Catheter ("Firefighter™"). The two experts spoke highly of its excellent crossability and compliance. The R&D staff also discussed with the two experts about the clinical needs of left aurcle occlude and drug eluting balloon, and collected information regarding CTO technique strategies and complex, high-risk patients management, to lay a solid foundation for further optimization of product performance.
 
After 15 years of development, Coronary Interventional Salon of China has developed into a clinical cardiovascular congress covering various academic topics. Lei Jiang, MicroPort® First Vice President of Domestic Coronary Sales & Marketing, said: "We arranged such kind of academic events with the hope of showcasing the excellent performance of our coronary products while enhancing the communication with physicians to keep improving our products based on their clinical needs, and thereby promote the development of treatment technology in China's interventional cardiology and benefit more domestic patients."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Signs Strategic Agreement with Wuhan Asian Industrial
[Next]:Firehawk® Gains Regulatory Approval in Taiwan